Literature DB >> 30947393

An Advanced Practice Practitioner-Based Program to Reduce 30- and 90-Day Readmissions After Liver Transplantation.

Nadim Mahmud1, Samantha Halpern2, Rebecca Farrell2, Kate Ventura2, Arwin Thomasson2, Heidi Lewis2, Kim M Olthoff2, Matthew H Levine2, Susanna Nazarian2, Vandana Khungar1.   

Abstract

Hospital readmissions after liver transplantation (LT) are common and associated with increased morbidity and cost. High readmission rates at our center motivated a change in practice with adoption of a nurse practitioner (NP)-based posttransplant care program. We sought to determine if this program was effective in reducing 30- and 90-day readmissions after LT and to identify variables associated with readmission. We performed a retrospective cohort study of all patients undergoing LT from July 1, 2014, to June 30, 2017, at a tertiary LT referral center. A NP-based posttransplant care program with weekend in-house nurse coordination providers and increased outpatient NP clinic availability was instituted on January 1, 2016. Postdischarge readmission rates at 30 and 90 days were compared in the pre-exposure and postexposure groups, adjusting for associated risk factors. A total of 362 patients were included in the analytic cohort. There were no significant differences in demographics, comorbidities, or index hospitalization characteristics between groups. In the adjusted analyses, the risk of readmission in the postexposure group was significantly reduced relative to baseline at 30 days (hazard ratio [HR] 0.60, 95% confidence interval [CI], 0.39-0.90; P = 0.02) and 90 days (HR, 0.49; 95% CI, 0.34-0.71; P < 0.001). Risk factors positively associated with 30-day readmission included peritransplant dialysis (HR, 1.70; 95% CI, 1.13-2.58; P = 0.01) and retransplant on index hospitalization (HR, 10.21; 95% CI, 3.39-30.75; P < 0.001). Male sex was protective against readmission (HR, 0.66; 95% CI, 0.45-0.97; P = 0.03). In conclusion, implementation of expanded NP-based care after LT was associated with significantly reduced 30- and 90-day readmission rates. LT centers and other service lines using significant postsurgical resources may be able to reduce readmissions through similar programs.
Copyright © 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2019        PMID: 30947393      PMCID: PMC6548546          DOI: 10.1002/lt.25466

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  20 in total

1.  Hospital readmissions among patients with decompensated cirrhosis.

Authors:  Michael L Volk; Rachel S Tocco; Jessica Bazick; Mina O Rakoski; Anna S Lok
Journal:  Am J Gastroenterol       Date:  2011-09-20       Impact factor: 10.864

2.  Clinical factors predicting readmission after orthotopic liver transplantation.

Authors:  Arema A Pereira; Renuka Bhattacharya; Robert Carithers; Jorge Reyes; James Perkins
Journal:  Liver Transpl       Date:  2012-09       Impact factor: 5.799

3.  Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease.

Authors:  Kenneth Berman; Sweta Tandra; Kate Forssell; Raj Vuppalanchi; Raj Vuppalanch; James R Burton; James Nguyen; Devonne Mullis; Paul Kwo; Naga Chalasani
Journal:  Clin Gastroenterol Hepatol       Date:  2010-11-17       Impact factor: 11.382

4.  Characteristics of hospitals receiving penalties under the Hospital Readmissions Reduction Program.

Authors:  Karen E Joynt; Ashish K Jha
Journal:  JAMA       Date:  2013-01-23       Impact factor: 56.272

Review 5.  Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice.

Authors:  Nathan D Shippee; Nilay D Shah; Carl R May; Frances S Mair; Victor M Montori
Journal:  J Clin Epidemiol       Date:  2012-10       Impact factor: 6.437

Review 6.  The influences of postdischarge management by nurse practitioners on hospital readmission for heart failure.

Authors:  Patricia Delgado-Passler; Ruth McCaffrey
Journal:  J Am Acad Nurse Pract       Date:  2006-04

7.  Defining readmission risk factors for liver transplantation recipients.

Authors:  Neil Shankar; Paul Marotta; William Wall; Mamoun Albasheer; Roberto Hernandez-Alejandro; Natasha Chandok
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-09

8.  The care transitions intervention: results of a randomized controlled trial.

Authors:  Eric A Coleman; Carla Parry; Sandra Chalmers; Sung-Joon Min
Journal:  Arch Intern Med       Date:  2006-09-25

9.  Cardiac acute care nurse practitioner and 30-day readmission.

Authors:  Daniel David; Lorraine Britting; Joanne Dalton
Journal:  J Cardiovasc Nurs       Date:  2015 May-Jun       Impact factor: 2.083

10.  Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.

Authors:  George N Ioannou; James D Perkins; Robert L Carithers
Journal:  Gastroenterology       Date:  2008-02-13       Impact factor: 22.682

View more
  3 in total

1.  Saudi association for the study of liver diseases and transplantation position statement on the hepatology workforce in Saudi Arabia.

Authors:  Bandar Al-Judaibi; M Katherine Dokus; Waleed Al-Hamoudi; Dieter Broering; Mohammad Mawardi; Nasser AlMasri; Mohammed Aljawad; Ibrahim H Altraif; Faisal Abaalkhail; Saleh A Alqahtani
Journal:  Saudi J Gastroenterol       Date:  2022 Mar-Apr       Impact factor: 2.485

2.  T2 Hepatocellular Carcinoma Exception Policies That Prolong Waiting Time Improve the Use of Evidence-based Treatment Practices.

Authors:  Claire Durkin; David E Kaplan; Therese Bittermann
Journal:  Transplant Direct       Date:  2020-08-21

Review 3.  Improving evidence-based grouping of transitional care strategies in hospital implementation using statistical tools and expert review.

Authors:  Jing Li; Gaixin Du; Jessica Miller Clouser; Arnold Stromberg; Glen Mays; Joann Sorra; Jane Brock; Terry Davis; Suzanne Mitchell; Huong Q Nguyen; Mark V Williams
Journal:  BMC Health Serv Res       Date:  2021-01-07       Impact factor: 2.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.